Related Experiment Videos
New experimental model of multiple myeloma
G B Telegin1, A R Kalinina, N A Ponomarenko
1Branch of M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Pushchino. telegin@fibkh.serpukhov.su
Abstract:
NSO/1 (P3x63Ay 8Ut) and SP20 myeloma cells were inoculated to BALB/c OlaHsd mice. NSO/1 cells allowed adequate stage-by-stage monitoring of tumor development. The adequacy of this model was confirmed in experiments with conventional cytostatics: prospidium and cytarabine caused necrosis of tumor cells and reduced animal mortality.
Insights
This study demonstrates that NSO/1 myeloma cells in mice provide a reliable model for monitoring tumor growth. Conventional cytostatics effectively reduced tumor cell necrosis and mortality in this model.
Area of Science:
- * Oncology and experimental immunology.
Background:
- * Development of reliable animal models is crucial for preclinical cancer research.
- * Myeloma cell lines are utilized to study tumor progression and therapeutic responses.
Purpose of the Study:
- * To evaluate the suitability of NSO/1 and SP20 myeloma cells in BALB/c mice as a model for tumor development.
- * To confirm the model's adequacy using conventional cytostatic drugs.
Main Methods:
- * Inoculation of NSO/1 and SP20 myeloma cells into BALB/c OlaHsd mice.
- * Monitoring of tumor development stages using NSO/1 cells.
- * Treatment of tumor-bearing mice with prospidium and cytarabine.
Main Results:
- * NSO/1 myeloma cells facilitated effective stage-by-stage monitoring of tumor progression.
- * Prospidium and cytarabine treatments resulted in significant tumor cell necrosis.
- * Conventional cytostatic treatment led to a reduction in animal mortality.
Conclusions:
- * The NSO/1 myeloma cell line in BALB/c mice represents an adequate model for preclinical studies.
- * This model is validated for assessing the efficacy of chemotherapeutic agents against myeloma.